厄贝沙坦联合氢氯噻嗪治疗老年高血压38例临床效果分析

Clinical efficacy analysis of Irbesartan joint with Hydrochlorothiazide therapy in elderly hypertension of 38 patients

目的探讨厄贝沙坦和氢氯噻嗪联用治疗老年高血压的临床效果及安全性。方法将门诊治疗的76例老年高血压患者随机分为观察组和对照组各38例,观察组口服厄贝沙坦氢氯噻嗪片(含厄贝沙坦150mg,氢氯噻嗪12.5mg),对照组口服厄贝沙坦150mg,每日1片,4周1个疗程,观察两组用药前后各类指标变化及降压效果。结果用药12周后,两组患者血压均较治疗前明显下降,治疗前后比较差异有统计学意义(P<0.05);治疗后两组血压比较差异无统计学意义(P>0.05);观察组治疗的总有效率明显高于对照组,且不良反应发生率明显低于对照组,两组比较差异均具有统计学意义(P<0.05)。结论厄贝沙坦联合氢氯噻嗪治疗老年高血压疗效确切,耐受性好,无明显不良反应,值得临床推广应用。

Objective To discuss about the clinical efficacy and safety of Irbesartan joint with Hydrochlorothiazide therapy in elderly hypertension of 38 patients. Methods Seventy-six elderly hypertension patients treated in our outpatient department were randomly divided into observation group and control group with 38 cases respectively. Patients in the observation group was treated with Irbesartan Hydrochlorothiazide tablets （containing irbesartan 150 mg and hydrochlorothiazide 12.5 mg）, while patients in the control group was treated with irbesartan 150 mg. A course of treatment lasted four weeks with 1 tablet per day was given. The changes of various indicators and antihypertensive effect were measured and compared between the two groups. Results Statistically significant difference （P 〈 0.05） exited in the blood pressure of both group after a 12-week respective treatment in comparison with that before the treatment in which patients in both group had lower blood pressure after treatment. No statistically significant difference （P 〉 0.05） exited in the blood pressure after treatment between the two groups. Statistically significant difference （P 〈 0.05） exited in total effective rate and the ratio to have adverse effects in which the observation group showed higher total effective rate and lower ratio to have adverse effects. Conclusion Irbesartan joint with Hydrochlorothiazide therapy is worth of widely clinical application with the characteristic of certain efficacy, well tolerance and little obvious adverse effects.